China’s National Medical Products Administration (NMPA) is seeking public comments on new regulations it is drafting on drug registration, drug distribution, and manufacturing. The new regulations, updated in October by the Ministry of Justice, reflect changes made to the Drug Administration Law slated to take effect December 1. Among the rules covered by the updates are guidelines for marketing authorization, for automatic approval of clinical trials and for the compassionate use of drugs. Comments must be received by November 14.
